Table 1.
Baseline characteristics of patients with severe tricuspid regurgitation
| Baseline characteristics | Total cohort (n = 435) |
|---|---|
| Demographics | |
| Age, years | 66.9 ± 18.5 |
| Female, n (%) | 251 (57.7%) |
| STS score for mortality, (%) | 6.7% |
| Comorbid conditions | |
| Atrial fibrillation/flutter, n (%) | 229 (52.6%) |
| Coronary artery disease, n (%) | 158 (36.3%) |
| History of CABG, n (%) | 51 (11.7%) |
| History of PCI, n (%) | 45 (10.3%) |
| Diabetes mellitus, n (%) | 126 (28.9%) |
| Chronic kidney disease, n (%) | 94 (21.6%) |
| Dialysis, n (%) | 34 (7.8%) |
| Hypertension, n (%) | 276 (63.4%) |
| Heart failure, n (%) | 268 (61.6%) |
| Peripheral artery disease, n (%) | 45 (10.3%) |
| Former or current smoker, n (%) | 137 (31.5%) |
| History of solid tumor, n (%) | 39 (8.9%) |
| History of stroke or TIA, n (%) | 79 (18.2%) |
| COPD, n (%) | 81 (18.6%) |
| Obstructive sleep apnea, n (%) | 43 (9.8%) |
| Interstitial lung disease, n (%) | 9 (2.0%) |
| Connective tissue disease, n (%) | 6 (1.3%) |
| Liver disease, n (%) | 63 (14.5%) |
| Laboratory data | |
| Hemoglobin, g/dL | 11.3 ± 2.5 |
| Creatinine, mg/dL | 1.58 ± 1.58 |
| INR of cohort | 1.63 |
| INR on AC | 1.89 |
| INR not on AC | 1.35 |
| AST/ALT of cohort | 52/40 U/L |
| AST/ALT on AC | 57/38 U/L |
| AST/ALT not on AC | 46/44 U/L |
| Medical therapy | |
| ACEi/ARB, n (%) | 105 (24.1%) |
| Beta blocker, n (%) | 173 (39.7%) |
| Calcium channel blocker, n (%) | 43 (9.8%) |
| Loop diuretic, n (%) | 176 (40.5%) |
| Thiazide diuretic, n (%) | 45 (10.3%) |
| Aldosterone antagonist, n (%) | 49 (11.2%) |
| Anticoagulation, n (%) | 129 (29.6%) |
| Antiarrhythmic, n (%) | 65 (14.9%) |
| Statin, n (%) | 133 (30.5%) |
AC, anticoagulation; ACEi, angiotensin-converting enzyme inhibitor; ALT, alanine aminotransferase; ARB, angiotensin receptor blocker; AST, aspartate transaminase; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; INR, international normalized ratio; PCI, percutaneous coronary intervention; STS, Society of Thoracic Surgeons; TIA, transient ischemic attack.
Reference ranges: aspartate transaminase (AST) and alanine aminotransferase (ALT) – <60 U/L and <41 U/L, respectively, creatinine – 0.7 to 1.3 mg/dL, hemoglobin – 13.5 to 17.5 g/dL, international normalized ratio (INR) – <1.2.